Unacknowledged Casualties

Media and Journalist Resources

For Journalists, Documentary Makers, Academics, and Policy Researchers

This page provides verification resources and story angles for journalists and researchers working on the ADF antimalarial drug trials and their consequences for veterans and their families. The full research report is available for download from the About page.

The Story in Summary

Between 1998 and 2002, approximately 3,000 ADF personnel were administered mefloquine and tafenoquine during deployments to East Timor and Bougainville, in significant part as formal clinical drug trials. Both drugs are now recognised by major regulatory agencies as carrying substantial neuropsychiatric risk, including effects that may persist permanently. This site details the domestic violence, coercive control, and family breakdown experienced by partners and children of affected veterans — and the failure of every relevant institution to recognise, investigate, or respond to that secondary harm.

Key Facts for Verification

Scale of the trials
Approximately 3,000 ADF personnel received mefloquine and/or tafenoquine, 1998–2002. An estimated 1,319 participated in mefloquine trials in East Timor alone. More than 1,540 were enrolled in tafenoquine studies across both deployment theatres.
Sources: QVFA Senate Submission 94; Royal Commission Final Report, Vol. 4, Ch. 22 (2024).
Dosing conditions
Standard approved prophylactic dose: 250 mg per week. ADF trial loading doses documented at up to 1,500 mg per week — six times the approved level. Tafenoquine trial subjects received up to 1,200 mg over three days.
Source: QVFA Senate Submission 94. Verify against primary AMI trial records for formal or legal use.
The FDA black box warning
The FDA issued its strongest safety warning for mefloquine in 2013, stating neuropsychiatric adverse reactions may persist and may in some cases become permanent. Listed effects include psychosis, hallucinations, suicidal ideation, and permanent balance disorders.
Source: FDA Drug Safety Communication, 2013. Available at fda.gov.
The tafenoquine neurotoxicity finding
In 2009, WRAIR laboratory studies found tafenoquine to be more neurotoxic than mefloquine. No longitudinal follow-up has been conducted on ADF tafenoquine trial subjects.
Sources: WRAIR research (2009); QVFA Senate Submission 94.
The Royal Commission
The Royal Commission into Defence and Veteran Suicide Final Report (September 2024) devoted Chapter 22 of Volume 4 to mefloquine and tafenoquine and recommended a brain injury program for affected veterans. The Australian Government accepted this in principle in December 2024. The program does not extend recognition to spouses or family members.
Source: Royal Commission Final Report, Vol. 4, Ch. 22; Australian Government response, December 2024.
Fort Bragg, 2002
Within approximately six weeks in the summer of 2002, four soldiers recently returned from Afghanistan killed their wives at Fort Bragg. Three subsequently killed themselves. The Army and CDC review attributed the events to PTSD without systematic investigation of mefloquine exposure. The pharmaceutical records of the deceased were not reviewed.
Sources: US Army and CDC Fort Bragg review (2002); Nevin and Ritchie, military psychiatry literature.

Underreported Angles

  • The missing coroner investigations. Numerous coronial inquests into suicides of ADF quinoline trial subjects have been completed without coroners receiving the relevant AMI trial pharmaceutical records. The quinoline nexus has never been formally investigated in the Australian coronial record.
  • The DVA incentive structure. The DVA entitlements system provides a financial pathway for veterans diagnosed with PTSD but not for those correctly diagnosed with quinoline-induced acquired brain injury. The system financially rewards the wrong diagnosis.
  • The redacted rejection. A proposed rehabilitation and research program was rejected by Defence. The government's four-page written justification was returned entirely redacted.
  • Children who joined the ADF. A completely undocumented intergenerational harm pathway: children who grew up in quinoline-affected households and subsequently enlisted, potentially exposed to the same class of drug during their own service.
  • The universal international gap. No country has established a recognition or support framework for secondary harm to the partners and families of quinoline-affected veterans.
  • The tafenoquine follow-up gap. More than 1,540 ADF personnel enrolled in tafenoquine trials. No longitudinal health studies have ever been conducted on this cohort.

Primary Source Access Pathways

  • FDA mefloquine black box warning and product label (2013): fda.gov
  • TGA Database of Adverse Event Notifications (DAEN): tga.gov.au
  • Royal Commission Final Report: defenceveteransuicide.royalcommission.gov.au
  • QVFA Senate Submission 94 (McCarthy): Australian Parliament House submissions portal
  • Senate Submission 73 (Quinn): Australian Parliament House submissions portal
  • Ritchie, Block and Nevin (2013): Journal of the American Academy of Psychiatry and the Law, Vol. 41(2)
  • Nevin and Ritchie (2016): Post-Traumatic Stress Disorder and Related Diseases in Combat Veterans, Springer International
Media enquiriesJournalists and documentary makers seeking interview access, background briefings, or access to the full research report are welcome to make contact.

[Contact form / email address]